 |
|
HuMax-CD4
A Fully Human Monoclonal Anti-CD4 Antibody for the Treatment of Psoriasis Vulgaris
Lone Skov, MD;
Knud Kragballe, MD;
Claus Zachariae, MD;
Erik R. Obitz, MD;
Elisabeth A. Holm, MD;
Gregor B. E. Jemec, MD;
Henrik Sølvsten, MD;
Hans H. Ibsen, MD;
Lone Knudsen, MD;
Pia Jensen, MScPharm;
Jan H. Petersen, DVM;
Torkil Menné, MD;
Ole Baadsgaard, MD
Arch Dermatol. 2003;139:1433-1439.
Background Psoriasis is characterized by infiltration with mononuclear cells. Especially activated memory CD4+ T cells are critical in the pathogenesis. Interaction between the CD4 receptor and the major histocompatibility complex class II molecule is important for T-cell activation.
Objective To test safety and efficacy of a fully human monoclonal anti-CD4 antibody (HuMax-CD4) in the treatment of psoriasis.
Design Multicenter, double-blind, placebo-controlled, randomized clinical trial.
Patients Eighty-five patients with moderate to severe psoriasis.
Interventions Subcutaneous infusions of placebo or HuMax-CD4 at doses of 20, 80, 160, or 280 mg once weekly for 4 weeks.
Main Outcome Measures Psoriasis Area and Severity Index (PASI), investigators' and patients' overall response assessment, adverse events, laboratory assessment including total T-cell and subtype counts, CD4 receptor occupancy, and interleukin 2 receptor levels.
Results At week 7, mean PASI was reduced in all treatment groups (95% confidence intervals are in parentheses): placebo, 8% (-3% to 19%); 20 mg, 12% (-6% to 27%); 80 mg, 14% (-14% to 35%); 160 mg, 16% (-4% to 33%); and 280 mg, 24% (-10% to 48%). At the highest dose level, 6 (38%) of 16 patients obtained more than 25% reduction of PASI and 3 (19%) obtained more than 50% reduction of PASI. A dose-dependent decrease in total lymphocyte count was seen and was parallel to a dose-dependent decrease in CD4+ T cells. This decrease was due to a decrease in the memory subset, whereas the naive subset was affected to a minor degree. Four weeks of treatment with HuMax-CD4 was safe and well tolerated.
Conclusions Treatment with HuMax-CD4 led to a moderate, not statistically significant reduction in PASI. The efficacy results obtained after only 4 weeks of treatment suggest that longer treatment would lead to even further reduction of PASI.
From the Department of Dermatology, Gentofte University Hospital, Gentofte, Denmark (Drs Skov, Zachariae, and Menné); Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark (Drs Kragballe and Obitz); Section of Dermatology, Department of Medicine, Roskilde Hospital, Roskilde, Denmark (Drs Holm and Jemec); Department of Dermatology, Odense University Hospital, Odense, Denmark (Drs Sølvsten and Ibsen); Department of Dermatology, Bispebjerg University Hospital, Copenhagen, Denmark (Dr Knudsen); and Genmab A/S, Copenhagen (Ms Jensen and Drs Petersen and Baadsgaard).
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
A Human CD4 Monoclonal Antibody for the Treatment of T-Cell Lymphoma Combines Inhibition of T-Cell Signaling by a Dual Mechanism with Potent Fc-Dependent Effector Activity
Rider et al.
Cancer Res. 2007;67:9945-9953.
ABSTRACT
| FULL TEXT
Toll-like Receptors in Tumor Immunotherapy
Paulos et al.
Clin. Cancer Res. 2007;13:5280-5289.
ABSTRACT
| FULL TEXT
Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma
Kim et al.
Blood 2007;109:4655-4662.
ABSTRACT
| FULL TEXT
|
